---
title: R&D AI Strategy 2026
doc_type: strategy
owner: ACME Pharma R&D Leadership
status: draft
company: ACME Pharma
confidentiality: Internal
scenario: AI in Research and Development planning evidence
Document_File_Name: 01_rd_ai_strategy_2026.md
IIA_Type: UNK
Quality_Rating: L
Relevance_Score: L
Fact: 'scenario: AI in Research and Development planning evidence. ACME Pharma R&D
  wants to use AI to improve research productivity without weakening research integrity,
  confidentiality, intellectual property protection, or regulatory readiness.'
Summary: 'title: R&D AI Strategy 2026. doc_type: strategy. owner: ACME Pharma R&D
  Leadership. status: draft. company: ACME Pharma. confidentiality: Internal. scenario:
  AI in Research and Development planning evidence. R&D AI Strategy 2026. Purpose.
  ACME Pharma R&D wants to use AI to improve research productivity without weakening
  research integrity, confidentiality, intellectual property protection, or regulatory
  readiness.'
Section_Context: Document overview
IIA_Relevance_Explanation: Listed to preserve coverage; manual review required to
  extract planning evidence.
IIA_Relevance: L
IIA_Confidence: L
Notes: Auto-derived from scan; verify content during manual review.
---

# R&D AI Strategy 2026


## Purpose

ACME Pharma R&D wants to use AI to improve research productivity without weakening research integrity, confidentiality, intellectual property protection, or regulatory readiness. The strategy covers four initial AI-enabled capabilities: literature review support, experiment design suggestions, lab-note synthesis, and candidate prioritization for early-stage research.

## Strategic objectives

1. Reduce the time required to summarize scientific publications and internal research notes.
2. Improve consistency of experiment planning by making prior assumptions, constraints, and open questions visible.
3. Support early hypothesis generation while keeping final research decisions with accountable scientists.
4. Protect confidential research data, trade secrets, unpublished results, and collaboration know-how.
5. Create a reusable governance pattern for future AI-enabled R&D use cases.

## Boundaries

The AI system may assist with search, summarization, classification, drafting, and comparison. It must not independently approve research direction, replace scientific peer review, approve regulatory claims, or decide whether a candidate moves to the next development phase.

The strategy assumes a phased rollout. Pilot use cases may run in a controlled sandbox using approved data sets. Any production use must pass security, legal, privacy, validation, and R&D governance review.

## Key decisions still open

- Whether external model providers may process unpublished research text.
- Whether any research data may be used for model training, fine-tuning, or vendor product improvement.
- Whether co-developed models or prompts are owned by the company, the vendor, or jointly.
- Whether cloud-hosted model endpoints satisfy R&D confidentiality and data residency expectations.
- How model outputs will be captured in research records when they influence decisions.

## ACME Pharma R&D operating context

ACME Pharma is a 50,000-employee global life-sciences company with a central R&D organization of roughly 9,000 employees and long-running partnerships with universities, contract research organizations, technology providers, and data vendors. The R&D AI program sits inside the Global Research Platforms group, but its users span discovery biology, translational science, preclinical safety, clinical pharmacology, biomarker science, regulatory science, and scientific knowledge management.

The current audit scope focuses on pre-approval R&D use cases, not commercial, manufacturing, or patient-facing medical advice. The highest-risk boundary is where AI output starts to influence a GxP-relevant decision, a regulatory submission support activity, or an electronic research record that could later be relied on for development decisions.

## AI use-case portfolio

| Portfolio area | Example use | Current boundary |
|---|---|---|
| Literature intelligence | Summarize publications, compare mechanisms of action, identify contradictory findings | Source-linked summaries only; no scientific conclusion without scientist sign-off |
| Experiment design challenge | Identify missing controls, likely confounders, and practical constraints | Advisory only; protocol owner remains accountable |
| Lab-note synthesis | Turn raw notes and assay observations into review drafts | No replacement of original records; source linkage required |
| Candidate prioritization | Rank early candidates using weighted evidence and uncertainty flags | Not a gate decision; ranking must be reviewed with primary evidence |
| Regulatory drafting support | Draft outline language from approved source documents | Not yet approved for submission-ready content |

## Governance decision points

The strategy requires a documented decision whenever a use case moves from public information to internal research data, from sandbox to routine use, from advisory output to decision support, or from non-GxP exploration to GxP-relevant evidence. Each transition requires evidence of data classification, intended use, human accountability, supplier restrictions, validation or assurance approach, and records-management expectations.

## Governance dependency added after inventory review

The strategy now requires the R&D Digital Office to maintain both an AI use-case inventory and an AI system inventory. Strategy approval is not enough to expand a pilot; the relevant use case and supporting system must both show owner, intended use, data class, supplier involvement, GxP boundary, lifecycle state, and monitoring expectations.

## 2026 implementation assumptions

The R&D AI strategy assumes that the first twelve months will remain a controlled adoption period. The Digital Office is expected to provide a common intake route, but scientific functions are still allowed to propose local use cases where the data, decision impact, and supplier footprint are documented before testing starts. This creates a deliberate tension: researchers want quick access to tools that remove manual literature and note-review work, while Quality, Legal/IP, Privacy, and Security expect evidence before any tool touches confidential material.

For planning purposes, the strategy separates three decision levels. Level 1 covers productivity support using public literature or training examples. Level 2 covers internal research material where outputs may influence study design, candidate prioritization, or portfolio discussion. Level 3 covers GxP-adjacent or submission-support activities where outputs could become part of an electronic record, validation package, regulatory response, or inspection-relevant rationale. The strategy says Level 3 is not prohibited, but it requires a documented intended-use statement, accountable process owner, quality review, traceability to source evidence, and a validation or computer software assurance rationale.

## Portfolio pressure points observed by the steering group

The strategy notes three pressure points that are likely to matter in an audit. First, individual teams are already using public AI assistants for literature summaries because approved internal tools are slower and less flexible. Second, several external research collaborations include AI-enabled analysis work even though the AI component is not always visible in the contract summary. Third, the difference between a research aid and a decision-support tool is not stable: a tool may begin as a drafting assistant, but its output can become influential once it appears in governance decks, candidate review packets, or study design notes.

The preferred control approach is therefore not to block all experimentation. It is to force visible classification and escalation when a use case crosses a boundary: public to internal data, non-confidential to confidential data, draft to decision support, single study to platform reuse, or sandbox to routine operation. The audit should test whether those boundaries are actually recognized in operating records, not only described in strategy slides.
